Nonlinear pharmacokinetics of fluvoxamine and gender differences

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Psychiatry

Background:

• Major depressive disorder is a common psychiatric condition.
• Selective serotonin reuptake inhibitors (SSRIs) are widely used for depression treatment.
• Understanding drug pharmacokinetics is crucial for optimizing treatment efficacy and safety.

Purpose of the Study:

• To assess fluvoxamine serum concentrations in patients with major depression.
• To investigate the pharmacokinetic variability of fluvoxamine at different fixed doses.
• To determine if fluvoxamine pharmacokinetics exhibit sex-dependent differences.

Main Methods:

• Prospective study design.
• Inclusion of 15 patients meeting DSM-III-R criteria for major depression.
• Fixed dosing regimen: 50 mg twice daily for 2 weeks, then 100 mg twice daily.
• Serum drug monitoring on days 14 and 28.

Main Results:

• Significant inter-patient variability in fluvoxamine serum concentrations observed.
• Doubling the fluvoxamine dose resulted in a disproportionate mean 3.4-fold increase in serum concentrations.
• A significantly more pronounced increase in men (4.6-fold) compared to women (2.4-fold) was noted (p < 0.05).

Conclusions:

• Fluvoxamine exhibits nonlinear pharmacokinetics.
• The pharmacokinetics of fluvoxamine are sex-dependent.
• These findings highlight the importance of considering individual variability and sex in fluvoxamine dosing and monitoring.